InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,804.00
(
0.64%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.46
(
-0.17%
)
Bitcoin
60,882.61
(
0.17%
)
Post# of 30387
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Kag

Send PM Follow Ignore
Followers 1
Posts 788
Boards Moderated 0
Alias Born 02/01/2006

Kag

Re: HALF FULL GLASS post# 2569

Friday, 03/17/2006 7:10:04 PM

Friday, March 17, 2006 7:10:04 PM

Post# of 30387
"Also we don't actually know what the licensing agreement allows Abbott to use..."

Half Full,
We do know what the BioCurex/Abbott licensing deal allows Abbott to use. The deal gives Abbott the worldwide rights to commercialize blood tests using BioCurex's RECAF technology. Abbott's goal is to further develop this technology, incorporating it into future tests ran on their automated Architect system, for use in cancer diagnosis and monitoring. It sounds like Abbott can develop as many RECAF blood tests as they want to. kag


Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up